TABLE 1.
Cord blood transplantation for adult T-cell leukemia-lymphoma.
| References | Pt. No. | Median age (range) | Sex M/F | Subtype | Disease status at CBT | Conditioning regimen | Cause of death | Outcome |
| Tamura et al., 2006 | 11 | 56 (39–61) | Unk | Unk | CR: 2 Non-CR: 9 | MAC: 2 RIC: 9 | TRM: 5 ATL: 5 | Unk |
| Hishizawa et al., 2010 | 90 | Unk | 52/38 | Unk | CR: 26 Non-CR: 57 Unk: 7 | MAC: 14 RIC: 64 Unk: 12 | TRM: 45 ATL: 25 Unk: 4 | 3Y-OS: 17% (95% CI 9–25) |
| Nakamura et al., 2012 | 10 | 51 (31–64) | 6/4 | Acute: 9 Lymphoma: 1 | CR: 2 PR: 4 SD: 1 PD: 3 | MAC: 6 RIC: 4 | ATL: 4 Sepsis: 1 GVHD + ATL: 1 | 2Y-OS: 40% (95% CI 67–12) |
| Ishida et al., 2013 | 174 | Unk | Unk | Unk | Unk | Unk | Unk | 3Y-OS: 21% (95% CI 15–29) |
| Fukushima et al., 2013 | 27 | 52 (41–63) | 18/9 | Acute: 17 Lymphoma: 10 | CR: 5 PR: 11 PIF: 5 REL: 6 | MAC: 9 RIC: 18 | TRM: 10 ATL: 9 | 3Y-OS: 27.4% |
| Kato et al., 2014 | 175 | 55 (27–79) | 105/70 | Unk: 175 | CR: 50 Non-CR: 116 Unk: 9 | MAC: 63 RIC: 108 Unk: 4 | TRM: 77 ATL: 52 | 2Y-OS: 20.6% (95% CI 14–27) |
| Choi et al., 2016 | 15 | 62 (55–69) | 8/7 | Acute: 13 Lymphoma: 2 | CR: 5 PR: 10 | RIC: 15 | TRM: 3 ATL: 4 | 2Y-OS: 53.3% |
| Tokunaga et al., 2018 | 150 | 61 (24–78) | 88/62 | Acute: 107 Lymphoma: 39 Other: 4 | CR: 62 PR: 86 Unk: 2 | MAC: 54 RIC: 95 Unk: 1 | TRM: 54 ATL 46 | 1Y-OS: 38.3% (95% CI 30–47) |
ATL, adult T-cell leukemia-lymphoma; CBT, cord blood transplantation; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; PIF, primary induction failure; REL, refractory after relapse; OS, overall survival; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; TRM, transplant-related mortality; GVHD, graft-versus-host disease; Unk, unknown.